Allergy and Immunology · Novi, MI
NPI
1124085436
Since 2006
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
44000 W 12 Mile Rd, Suite 212
Novi, MI, 48377
Phone (248) 347-8285
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,271
688 services
Medicare patients, 2024
37
Average age 70
Drug cost, 2024
$1.2M
506 prescriptions
Company payments, 2025
$877
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Malathi Bathija was code 99213 (office e&m - established), 46 times for 27 patients. In total Malathi Bathija billed 688 services in 11 codes, and Medicare paid $9,271.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-01-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 46 | 27 | $68.83 | $3,166 |
| 99214 Office E&M - Established | Office | 17 | 12 | $91.85 | $1,561 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 17 | 14 | $13.14 | $223 |
| 99203 Office E&M - New | Office | 12 | 12 | $77.48 | $930 |
By year: 2022 $7,265 for 385 services; 2023 $6,945 for 385 services; 2024 $9,271 for 688 services.
Medicare prescription drug claims, 2024
In 2024, the drug Malathi Bathija prescribed most often to Medicare patients was Xolair (Omalizumab), with 62 prescriptions and refills. In total Malathi Bathija wrote 506 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xolair Omalizumab | 62 | 62 | Under 11 | $228K |
| Hyqvia Igg/Hyaluronidase,recombinant | 61 | 61 | Under 11 | $462K |
| Montelukast Sodium Generic | 55 | 147 | 20 | $586 |
| Azelastine Hcl Generic | 47 | 89 | 17 | $976 |
| Dupixent Syringe Dupilumab | 36 | 36 | Under 11 | $135K |
| Fluticasone Propionate Generic | 36 | 71 | 13 | $511 |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 32 | 32 | Under 11 | $163K |
| Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 | 24 | 24 | Under 11 | $91K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 24 | 27 | 12 | $1,169 |
| Epinephrine Generic | 24 | 25 | 21 | $7,272 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 15 | 25 | Under 11 | $15K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 13 | 25 | Under 11 | $3,519 |
| Dupixent Pen Dupilumab | 12 | 12 | Under 11 | $44K |
Brand drugs: 317 claims; generic drugs: 189 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Malathi Bathija $877 ($877 in general payments such as food, travel and fees) from 11 companies. The largest payer was CSL Behring with $156.
| Company | Payments | Amount |
|---|---|---|
| CSL Behring CSL.AX | 7 | $156 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $131 |
| GlaxoSmithKline, LLC. GSK | 5 | $104 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $99.95 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $99.02 |
| Genzyme Corporation SNY | 4 | $94.41 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 2 | $51.53 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $50.59 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $41.73 |
| Pharming Healthcare, Inc. | 1 | $27.91 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.